Výsledky vyhledávání - "Michaela Sousares"

Akademický článek

microRNA-2110 functions as an onco-suppressor in neuroblastoma by directly targeting Tsukushi.

Autor: Zhenze Zhao, Veronica Partridge, Michaela Sousares, Spencer D Shelton, Cory L Holland, Alexander Pertsemlidis, Liqin Du

Publikováno v: PLoS ONE, Vol 13, Iss 12, p e0208777 (2018)

microRNA-2110 (miR-2110) was previously identified as inducing neurite outgrowth in a neuroblastoma cell lines BE(2)-C, suggesting its differentiation-inducing and oncosuppressive function in neuroblastoma. In this study, we demonstrated that synthet

Externí odkaz: https://doaj.org/article/f51b1abfd38b4550aa111eb8eade0663

Zobrazit plný text záznamu

Plný text ve formátu HTML

817 Engineered toxin body targeting CTLA-4 (MT-8421) depletes Tregs in the tumor microenvironment and synergizes with αPD-1 to enhance T cell immunity

Autor: Lauren Byrne, Swati Khanna, Rebecca Martin, Caleigh Howard, Lilia Rabia, Michaela Sousares, Jay Zhao, John Majercak, Eric Poma, Chris Moore

Publikováno v: Regular and Young Investigator Award Abstracts.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a5d1ae9ea8f4bdf10ea54a1eb1e43af
https://doi.org/10.1136/jitc-2022-sitc2022.0817

Zobrazit plný text záznamu

Abstract 3543: Altering tumor immunophenotypes with PD-L1 engineered toxin bodies

Autor: Swati Khanna, Elizabeth M. Kapeel, Lauren R. Byrne, Elizabeth Saputra, Steven Rivera, Lindsey Aschenbach, Lilia A. Rabia, Garrett L. Cornelison, Rachael M. Orlandella, Brigitte Brieschke, Michaela Sousares, Jay Zhao, Garrett L. Robinson, Chris Moore, Joseph D. Dekker

Publikováno v: Cancer Research. 82:3543-3543

Targeting of PD-L1 checkpoint has shown clinical efficacy in multiple solid tumor indications. Currently approved PD-L1 targeted approaches rely on the blocking activity of monoclonal antibodies (mAbs) which sterically inhibit PD-L1 thus preventing P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c2dbc19c675d76e5455c7b7a21f5cb7
https://doi.org/10.1158/1538-7445.am2022-3543

Zobrazit plný text záznamu

Abstract 1628: Engineered toxin bodies targeting PD-L1 to alter tumor immunophenotypes and deliver broad antigenic diversity and patient coverage

Autor: Swati Khanna, Joseph D. Dekker, Betty Chang, Lilia A. Rabia, Garrett L. Robinson, Hilario J. Ramos, Garrett L. Cornelison, Elizabeth Saputra, Wenzhao Dong, Michaela Sousares, Jay Zhao, Lindsey Aschenbach

Publikováno v: Cancer Research. 81:1628-1628

Targeting PD-L1 has shown clinical efficacy in multiple solid tumor indications. Currently approved PD-L1 targeted approaches rely on monoclonal antibodies which sterically inhibit PD-L1 and prevent PD-1 mediated checkpoint activity. While these mole

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5c7c64bc122dc64e14639891733e046
https://doi.org/10.1158/1538-7445.am2021-1628

Zobrazit plný text záznamu

MicroRNAs in neuroblastoma differentiation and differentiation therapy

Autor: Shannon E. Weigum, Michaela Sousares, Liqin Du, Veronica Partridge

Publikováno v: Advances in Modern Oncology Research, Vol 3, Iss 5, Pp 213-222 (2017)

Neuroblastoma is one of the most common and aggressive types of pediatric cancers, making up about 7% of all childhood cancers. Neuroblastoma arises from the failure of neural crest cell precursors to differentiate, and inducing cell differentiation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6d7e47797ff73be2351c9c9cc31ee2b
https://doi.org/10.18282/amor.v3.i5.233

Zobrazit plný text záznamu

Current understanding on the role of cell cycle regulators in neuroblastoma cell differentiation

Autor: Liqin Du, Veronica Partridge, Michaela Sousares, Zhenze Zhao

Publikováno v: Med One, Vol 2, Iss 3 (2017)

Neuroblastoma is a pediatric cancer that arises from neural crest cells failing to differentiate into mature neuronal cells. Differentiation therapy is one of the effective approaches to treat high-risk neuroblastoma. Developing new differentiation a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27aea95b71ea12aec36dd64381f4fcfb
https://doi.org/10.20900/mo.20170010

Zobrazit plný text záznamu

Abstract 3900: The Safety and efficacy profile of a PD-L1 directed, Engineered Toxin Body, as a novel targeted direct-cell kill approach for the treatment of PD-L1 expressing cancers

Autor: Garrett L. Robinson, Jack P. Higgins, Brigitte Brieschke, Michaela Sousares, Hilario J. Ramos, Jensing Liu, Sara Le Mar, Veronica Partridge, Erin Willert, Joseph D. Dekker, Shaoyou Chu, Pablo A. Maceda, Aimee Iberg, Asis K. Sarkar

Publikováno v: Cancer Research. 79:3900-3900

Engineered Toxin Bodies (ETBs) are comprised of a deimmunized Shiga-like toxin subunit A (SLTA) genetically fused to an antibody-like targeting domain. The antibody targeting domain allows for specific targeting of cancer cells while the SLTA compone

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f024970a13557d5364526260a0dc752
https://doi.org/10.1158/1538-7445.am2019-3900

Zobrazit plný text záznamu